• Home
  • Print
  • About GeNeuro
  • Technologies
  • Investors and Partnering
  • News & Press
  • Patients
  • Careers
  • Contact
  • Recent scientific publications
  • Key scientific Publications
  • Press Articles

News

8th February 2012, Geneva, Switzerland. GeNeuro SA announces today the successful completion of its phase I clinical study with GNbAC1, a humanized monoclonal antibody targeting a human endogenous retrovirus, to treat multiple sclerosis.

 

 

8th February 2012, Plan-les-Ouates, Geneva, Switzerland. GeNeuro SA announces today the successful completion of its phase I clinical study with GNbAC1, a humanized monoclonal antibody targeting a human endogenous retrovirus, to treat multiple sclerosis. The randomized, double-blind, placebo-controlled, phase I study of single ascending intravenous doses of GNbAC1 in healthy volunteers demonstrated that GNbAC1 is very well tolerated.


 

18, chemin des Aulx, CH-1228 Plan-les-Ouates - Geneva, Switzerland | Tel: +41 22 794 50 85 | E-mail : contact@geneuro.com
© 2011 GeNeuro SA